Get Live Data

focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE
Stephen Yiu, FM at WS Blue Whale, discusses Nvidia, Visa/Mastercard, Lam Research & Allied Materials
Stephen Yiu, FM at WS Blue Whale, discusses Nvidia, Visa/Mastercard, Lam Research & Allied MaterialsView Video
Ben Turney, CEO at Kavango Resources, explains the company's progress from exploration to mining
Ben Turney, CEO at Kavango Resources, explains the company's progress from exploration to miningView Video

Latest Share Chat

  2. Share Prices
  3. GWP.L Share Price
  4. GWP.L Share News
  5. GW Pharmaceuticals Prices ADS Offering, Raising USD252 Million (ALLISS)

Pin to quick picksGWP.L Share News (GWP)

GWP.L Information
  • There is currently no data for GWP

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

GW Pharmaceuticals Prices ADS Offering, Raising USD252 Million (ALLISS)

Wed, 13th Jul 2016 07:00

LONDON (Alliance News) - AIM and Nasdaq listed GW Pharmaceuticals PLC on Wednesday said it had priced its offering of 2.8 million American Depositary Shares at USD90.00, raising around USD252.0 million.

The ADSs represent 33.6 million ordinary shares in the company.

Morgan Stanley, Bank of America Merrill Lynch and Goldman Sachs & Co are joint book-running managers for the offering, expected to close next Monday.

GW Pharmaceuticals has granted the underwriters a 30-day option to buy up to an additional 420,000 ADS' at the public offering price.

By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews

Copyright 2016 Alliance News Limited. All Rights Reserved.

More News
28 Apr 2015 07:30

GW Pharma In US Offering Of American Depositary Shares (ALLISS)

Read more
27 Apr 2015 11:09

GW Pharmaceuticals Gets Notice Of Allowance On Cannabidivarin Patent

Read more
23 Apr 2015 07:03

GW Pharmaceuticals Says New Physician Report Data Supports Epidiolex

Read more
21 Apr 2015 11:09

GW Pharmaceuticals Starts Second Phase III Trial For Epidiolex

Read more
14 Apr 2015 12:29

BUZZ-GW Pharmaceuticals Plc: Data on epilepsy drug shows promise

** U.S.-listed shares of London-based maker of cannabis-based drugs up about 9 pct at $104.77 premarket ** Company's childhood epilepsy drug, epidiolex, currently in use through an expanded access program, showed marked improvement in median reduction of seizure frequency, data compiled by

Read more
14 Apr 2015 07:48

GW Pharmaceuticals Says AAN Highlights Epidiolex In New Report

Read more
31 Mar 2015 15:35

BUZZ-U.S. STOCKS ON THE MOVE-Rada Electronic, Intercept Pharma, Alon USA

(For faster updates on individual market-movers, Eikon users please use search string "STXBZ US"; for the Day Ahead newsletter, http://link.reuters.com/mex49s; for the Morning News Call newsletter, http://link.reuters.com/nex49s) U.S. stocks fell on Tuesday in a modest retreat from the previous

Read more
31 Mar 2015 14:00

BUZZ-U.S. STOCKS ON THE MOVE-Lorillard, Charter Communications, Synta Pharma

(For faster updates on individual market-movers, Eikon users please use search string "STXBZ US"; for the Day Ahead newsletter, http://link.reuters.com/mex49s; for the Morning News Call newsletter, http://link.reuters.com/nex49s) U.S. stocks fell at the open on Tuesday, slightly reversing the pr

Read more
31 Mar 2015 13:25

BUZZ-U.S. STOCKS ON THE MOVE-Conn's, Lorillard, GW Pharma, DryShips

(For faster updates on individual market-movers, Eikon users please use search string "STXBZ US"; for the Day Ahead newsletter, http://link.reuters.com/mex49s; for the Morning News Call newsletter, http://link.reuters.com/nex49s) U.S. stock were poised to open lower on Tuesday, indicating a mode

Read more
31 Mar 2015 12:27

BUZZ-GW Pharma Plc: Commences trial to test cannabis-based drug in Dravet syndrome

** U.S.-listed shares of the maker of cannabis-based drugs up 4 pct at $91.99 premarket ** The UK-based company has started the second leg of a mid-stage trial testing Epidiolex to treat Dravet syndrome, a rare, treatment-resistant form of childhood epilepsy ** Data from the trial is

Read more
31 Mar 2015 11:21

GW Pharmaceuticals Begins Phase III Epidiolex Trial In Dravet Syndrome

Read more
13 Feb 2015 14:39

UK DIRECTOR DEALINGS SUMMARY: Scholium Team Buys After Profit Warning

Read more
9 Feb 2015 17:35

DIRECTOR DEALINGS: GW Pharmaceuticals COO Sells 10,000 Shares

Read more
5 Feb 2015 08:33

UK MORNING BRIEFING: BT Leads FTSE 100 On EE Deal Confirmation

Read more
5 Feb 2015 06:24

UK AGM, EGM Calendar - Week Ahead

Read more
12345678910

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.